Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-12

AUTHORS

Milind M Javle, Rachna T Shroff, Henry Xiong, Gauri A Varadhachary, David Fogelman, Shrikanth A Reddy, Darren Davis, Yujian Zhang, Robert A Wolff, James L Abbruzzese

ABSTRACT

BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models. METHODS: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN. RESULTS: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n = 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers. CONCLUSIONS: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer. TRIAL REGISTRATION: TRIAL REGISTRATION: STUDY A: NCT 0075647. STUDY B: NCT00640978. More... »

PAGES

368

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-10-368

DOI

http://dx.doi.org/10.1186/1471-2407-10-368

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008418244

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20630061


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erlotinib Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorescent Antibody Technique", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Epidermal Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Javle", 
        "givenName": "Milind M", 
        "id": "sg:person.01170552013.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170552013.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shroff", 
        "givenName": "Rachna T", 
        "id": "sg:person.01120712765.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120712765.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer and Blood Disorders", 
          "id": "https://www.grid.ac/institutes/grid.477919.5", 
          "name": [
            "Center for Cancer and Blood Disorders, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Henry", 
        "id": "sg:person.016444546257.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Varadhachary", 
        "givenName": "Gauri A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fogelman", 
        "givenName": "David", 
        "id": "sg:person.01137701711.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137701711.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reddy", 
        "givenName": "Shrikanth A", 
        "id": "sg:person.012547340642.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012547340642.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "Darren", 
        "id": "sg:person.01143530612.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143530612.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Yujian", 
        "id": "sg:person.01240504261.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240504261.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolff", 
        "givenName": "Robert A", 
        "id": "sg:person.01133335751.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abbruzzese", 
        "givenName": "James L", 
        "id": "sg:person.0645263515.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645263515.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/01.cco.0000143964.74936.d1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003424823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cco.0000143964.74936.d1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003424823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cco.0000143964.74936.d1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003424823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-06-0166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004420604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.07.9525", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005176755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1209990", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008091156", 
          "https://doi.org/10.1038/sj.onc.1209990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1209990", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008091156", 
          "https://doi.org/10.1038/sj.onc.1209990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbrc.2005.03.166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017102714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.274.14.9351", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025560502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.18.9514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027093675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-0736-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027724077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-04-1655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031995280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032812682", 
          "https://doi.org/10.1038/sj.onc.1207902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032812682", 
          "https://doi.org/10.1038/sj.onc.1207902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(94)90004-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038163610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(94)90004-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038163610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1167/iovs.09-3617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039803253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.23810", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043582157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-07-6720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044217275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.5482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044922442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf274", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052882288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077005576", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.8051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079372639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.6.2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083106816"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-12", 
    "datePublishedReg": "2010-12-01", 
    "description": "BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models.\nMETHODS: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN.\nRESULTS: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n = 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers.\nCONCLUSIONS: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer.\nTRIAL REGISTRATION: \nTRIAL REGISTRATION: \nSTUDY A: NCT 0075647.\nSTUDY B: NCT00640978.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2407-10-368", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies", 
    "pagination": "368", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "281ab38f4cfcaf81d5778fb8e311a66c20bc75ac9be297f2bf7040ca8b32950e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20630061"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-10-368"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008418244"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-10-368", 
      "https://app.dimensions.ai/details/publication/pub.1008418244"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2407-10-368"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      21 PREDICATES      76 URIs      48 LITERALS      36 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-10-368 schema:about N0c8f22197e3a4f638029af059aba753f
2 N14cc4fc855f04189ac9b52a88a4ad1bd
3 N1a1ef8c93d48473ca3b09df450df9aab
4 N1cc3a1c76aa44c788edb12c6f8fd2659
5 N1d4a10115293426193bfd50312df4954
6 N1e62c57daec8499b88977c88f5718fec
7 N3155234f6d2e4ee2a8e47e93f07087a5
8 N3dda3f4c8f584ca08aefe4b239511219
9 N4652f3af50084c8c8f42f90be3a09174
10 N4d8ee7186724404d97c5963104f7159e
11 N51c048c4450f431eb96dfbc61afeb097
12 N6d7c16e09b784e428db6fd5850ce08a1
13 N72c5d8c598094b11814ed20c79694329
14 N7b01aa2adcf54d7e8372198f10063475
15 N81558b00919444a6b25f99a6bbfcbabe
16 N8719338fc6b44d7394ff537124726288
17 N8cbd0d0a709a4c1d918744d350771e0b
18 N9935a707351844228caa73ce7e15229a
19 N99cbd64222c245f7a13817483b16172a
20 N9f833627766c47a2987715612897c79b
21 Naca405ec7ee5494ab7b418c557a07c5d
22 Naf030cd428244138a0a7ba0601f0387d
23 Nbee778285c8e4f36909fa11359a29f16
24 Ndffaad4487c64020aed14f1968f70ca2
25 Ne3facf2bde2a4f1fa3c1949a4d68c756
26 Nef2ec3808cb34e4d9bbc9018f58506c4
27 Nfee753573bf54714bc979462dd55f3e8
28 anzsrc-for:11
29 anzsrc-for:1112
30 schema:author N7defd54f4b3947c496e19de9d62ab50b
31 schema:citation sg:pub.10.1038/sj.onc.1207902
32 sg:pub.10.1038/sj.onc.1209990
33 https://app.dimensions.ai/details/publication/pub.1077005576
34 https://doi.org/10.1002/cncr.23810
35 https://doi.org/10.1016/0197-2456(94)90004-3
36 https://doi.org/10.1016/j.bbrc.2005.03.166
37 https://doi.org/10.1016/j.ejca.2008.10.026
38 https://doi.org/10.1074/jbc.274.14.9351
39 https://doi.org/10.1093/annonc/mdf274
40 https://doi.org/10.1097/01.cco.0000143964.74936.d1
41 https://doi.org/10.1158/0008-5472.can-07-6720
42 https://doi.org/10.1158/1078-0432.ccr-04-1655
43 https://doi.org/10.1158/1078-0432.ccr-0736-3
44 https://doi.org/10.1158/1535-7163.mct-06-0166
45 https://doi.org/10.1167/iovs.09-3617
46 https://doi.org/10.1200/jco.1997.15.6.2403
47 https://doi.org/10.1200/jco.2006.07.9525
48 https://doi.org/10.1200/jco.2007.14.5482
49 https://doi.org/10.1200/jco.2008.18.9514
50 https://doi.org/10.1200/jco.2008.26.15_suppl.8051
51 schema:datePublished 2010-12
52 schema:datePublishedReg 2010-12-01
53 schema:description BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models. METHODS: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN. RESULTS: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n = 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers. CONCLUSIONS: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer. TRIAL REGISTRATION: TRIAL REGISTRATION: STUDY A: NCT 0075647. STUDY B: NCT00640978.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree true
57 schema:isPartOf N08b4b4a7cd934c0f85e2cb06406e6250
58 N87c6ea5e9efc4d02878db09dc3896bd7
59 sg:journal.1024632
60 schema:name Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
61 schema:pagination 368
62 schema:productId N66da37d8e5714c33a20bb668a1dfe196
63 N685cecdc1cc449a0b62df2dcea566798
64 N9fe55b8d5ffc4f1cb506b3869c23bdc1
65 Na3962a5bb287434692044a48d9fc1531
66 Nbeeda1bfd6f94c0f8c3a059185cf531d
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008418244
68 https://doi.org/10.1186/1471-2407-10-368
69 schema:sdDatePublished 2019-04-10T16:41
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N93e7cfd66d824fc5b8835b5730b47b71
72 schema:url http://link.springer.com/10.1186%2F1471-2407-10-368
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N01e3f4bbaffa420cba501d9560201fbe rdf:first sg:person.01133335751.97
77 rdf:rest N8cb6562d1baf43e2acd661b24cf29bb4
78 N08b4b4a7cd934c0f85e2cb06406e6250 schema:volumeNumber 10
79 rdf:type schema:PublicationVolume
80 N0c8f22197e3a4f638029af059aba753f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Adenocarcinoma
82 rdf:type schema:DefinedTerm
83 N14cc4fc855f04189ac9b52a88a4ad1bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Male
85 rdf:type schema:DefinedTerm
86 N15fb3033e8a94d27b61978728cf9b7e8 schema:name Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA
87 rdf:type schema:Organization
88 N1a1ef8c93d48473ca3b09df450df9aab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Adult
90 rdf:type schema:DefinedTerm
91 N1cc3a1c76aa44c788edb12c6f8fd2659 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Immunosuppressive Agents
93 rdf:type schema:DefinedTerm
94 N1d4a10115293426193bfd50312df4954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 N1e62c57daec8499b88977c88f5718fec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Quinazolines
99 rdf:type schema:DefinedTerm
100 N2cb29636275d467a82ac5b30ccc19603 schema:name Apocell Inc, 2575 West Bellfort, Suite 190, Houston, TX, USA
101 rdf:type schema:Organization
102 N3155234f6d2e4ee2a8e47e93f07087a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Female
104 rdf:type schema:DefinedTerm
105 N3dda3f4c8f584ca08aefe4b239511219 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Aged
107 rdf:type schema:DefinedTerm
108 N4652f3af50084c8c8f42f90be3a09174 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Fluorescent Antibody Technique
110 rdf:type schema:DefinedTerm
111 N4d8ee7186724404d97c5963104f7159e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Immunoenzyme Techniques
113 rdf:type schema:DefinedTerm
114 N4f01f6c3160c4ddc8c43296ce72f775e rdf:first sg:person.01143530612.06
115 rdf:rest Nd7c96d6243774eadae7673a68e3f8635
116 N51c048c4450f431eb96dfbc61afeb097 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prognosis
118 rdf:type schema:DefinedTerm
119 N552f4a29c42a4339b2b7c63f16119999 rdf:first sg:person.012547340642.09
120 rdf:rest N4f01f6c3160c4ddc8c43296ce72f775e
121 N62dab131bae445878922a3124cdf7060 rdf:first sg:person.016444546257.55
122 rdf:rest N98b1a68c01a741a590f57e350b1b10e5
123 N66da37d8e5714c33a20bb668a1dfe196 schema:name pubmed_id
124 schema:value 20630061
125 rdf:type schema:PropertyValue
126 N685cecdc1cc449a0b62df2dcea566798 schema:name dimensions_id
127 schema:value pub.1008418244
128 rdf:type schema:PropertyValue
129 N6d7c16e09b784e428db6fd5850ce08a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name TOR Serine-Threonine Kinases
131 rdf:type schema:DefinedTerm
132 N72c5d8c598094b11814ed20c79694329 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Antineoplastic Combined Chemotherapy Protocols
134 rdf:type schema:DefinedTerm
135 N7b01aa2adcf54d7e8372198f10063475 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Phosphorylation
137 rdf:type schema:DefinedTerm
138 N7defd54f4b3947c496e19de9d62ab50b rdf:first sg:person.01170552013.73
139 rdf:rest Ne17af40f632043649af5cac3dc99438b
140 N81558b00919444a6b25f99a6bbfcbabe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Pancreatic Neoplasms
142 rdf:type schema:DefinedTerm
143 N8719338fc6b44d7394ff537124726288 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Signal Transduction
145 rdf:type schema:DefinedTerm
146 N87c6ea5e9efc4d02878db09dc3896bd7 schema:issueNumber 1
147 rdf:type schema:PublicationIssue
148 N8cb6562d1baf43e2acd661b24cf29bb4 rdf:first sg:person.0645263515.62
149 rdf:rest rdf:nil
150 N8cbd0d0a709a4c1d918744d350771e0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Erlotinib Hydrochloride
152 rdf:type schema:DefinedTerm
153 N93e7cfd66d824fc5b8835b5730b47b71 schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 N98b1a68c01a741a590f57e350b1b10e5 rdf:first Nd0c2c9c6c08f40b28798b1f000ff6d9e
156 rdf:rest Ne8dd12a29ffe4875b785c694e61ff979
157 N9935a707351844228caa73ce7e15229a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Survival Rate
159 rdf:type schema:DefinedTerm
160 N99cbd64222c245f7a13817483b16172a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Sirolimus
162 rdf:type schema:DefinedTerm
163 N9f833627766c47a2987715612897c79b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Receptor, Epidermal Growth Factor
165 rdf:type schema:DefinedTerm
166 N9fe55b8d5ffc4f1cb506b3869c23bdc1 schema:name nlm_unique_id
167 schema:value 100967800
168 rdf:type schema:PropertyValue
169 Na3962a5bb287434692044a48d9fc1531 schema:name readcube_id
170 schema:value 281ab38f4cfcaf81d5778fb8e311a66c20bc75ac9be297f2bf7040ca8b32950e
171 rdf:type schema:PropertyValue
172 Naca405ec7ee5494ab7b418c557a07c5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Proto-Oncogene Proteins c-akt
174 rdf:type schema:DefinedTerm
175 Naf030cd428244138a0a7ba0601f0387d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Middle Aged
177 rdf:type schema:DefinedTerm
178 Nbee778285c8e4f36909fa11359a29f16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Everolimus
180 rdf:type schema:DefinedTerm
181 Nbeeda1bfd6f94c0f8c3a059185cf531d schema:name doi
182 schema:value 10.1186/1471-2407-10-368
183 rdf:type schema:PropertyValue
184 Nd0c2c9c6c08f40b28798b1f000ff6d9e schema:affiliation https://www.grid.ac/institutes/grid.240145.6
185 schema:familyName Varadhachary
186 schema:givenName Gauri A
187 rdf:type schema:Person
188 Nd7c96d6243774eadae7673a68e3f8635 rdf:first sg:person.01240504261.54
189 rdf:rest N01e3f4bbaffa420cba501d9560201fbe
190 Ndffaad4487c64020aed14f1968f70ca2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Biomarkers, Tumor
192 rdf:type schema:DefinedTerm
193 Ne17af40f632043649af5cac3dc99438b rdf:first sg:person.01120712765.07
194 rdf:rest N62dab131bae445878922a3124cdf7060
195 Ne3facf2bde2a4f1fa3c1949a4d68c756 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Prospective Studies
197 rdf:type schema:DefinedTerm
198 Ne8dd12a29ffe4875b785c694e61ff979 rdf:first sg:person.01137701711.27
199 rdf:rest N552f4a29c42a4339b2b7c63f16119999
200 Nef2ec3808cb34e4d9bbc9018f58506c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Protein Kinase Inhibitors
202 rdf:type schema:DefinedTerm
203 Nfee753573bf54714bc979462dd55f3e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Neoplasm Staging
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
210 schema:name Oncology and Carcinogenesis
211 rdf:type schema:DefinedTerm
212 sg:journal.1024632 schema:issn 1471-2407
213 schema:name BMC Cancer
214 rdf:type schema:Periodical
215 sg:person.01120712765.07 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
216 schema:familyName Shroff
217 schema:givenName Rachna T
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120712765.07
219 rdf:type schema:Person
220 sg:person.01133335751.97 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
221 schema:familyName Wolff
222 schema:givenName Robert A
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97
224 rdf:type schema:Person
225 sg:person.01137701711.27 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
226 schema:familyName Fogelman
227 schema:givenName David
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137701711.27
229 rdf:type schema:Person
230 sg:person.01143530612.06 schema:affiliation N15fb3033e8a94d27b61978728cf9b7e8
231 schema:familyName Davis
232 schema:givenName Darren
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143530612.06
234 rdf:type schema:Person
235 sg:person.01170552013.73 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
236 schema:familyName Javle
237 schema:givenName Milind M
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170552013.73
239 rdf:type schema:Person
240 sg:person.01240504261.54 schema:affiliation N2cb29636275d467a82ac5b30ccc19603
241 schema:familyName Zhang
242 schema:givenName Yujian
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240504261.54
244 rdf:type schema:Person
245 sg:person.012547340642.09 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
246 schema:familyName Reddy
247 schema:givenName Shrikanth A
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012547340642.09
249 rdf:type schema:Person
250 sg:person.016444546257.55 schema:affiliation https://www.grid.ac/institutes/grid.477919.5
251 schema:familyName Xiong
252 schema:givenName Henry
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55
254 rdf:type schema:Person
255 sg:person.0645263515.62 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
256 schema:familyName Abbruzzese
257 schema:givenName James L
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645263515.62
259 rdf:type schema:Person
260 sg:pub.10.1038/sj.onc.1207902 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032812682
261 https://doi.org/10.1038/sj.onc.1207902
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/sj.onc.1209990 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008091156
264 https://doi.org/10.1038/sj.onc.1209990
265 rdf:type schema:CreativeWork
266 https://app.dimensions.ai/details/publication/pub.1077005576 schema:CreativeWork
267 https://doi.org/10.1002/cncr.23810 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043582157
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1016/0197-2456(94)90004-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038163610
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1016/j.bbrc.2005.03.166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017102714
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1074/jbc.274.14.9351 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025560502
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1093/annonc/mdf274 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052882288
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1097/01.cco.0000143964.74936.d1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003424823
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1158/0008-5472.can-07-6720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044217275
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1158/1078-0432.ccr-04-1655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031995280
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1158/1078-0432.ccr-0736-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027724077
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1158/1535-7163.mct-06-0166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004420604
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1167/iovs.09-3617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039803253
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1200/jco.1997.15.6.2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083106816
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1200/jco.2006.07.9525 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005176755
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1200/jco.2007.14.5482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044922442
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1200/jco.2008.18.9514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027093675
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1200/jco.2008.26.15_suppl.8051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079372639
300 rdf:type schema:CreativeWork
301 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
302 schema:name Department of Gastrointestinal Medical Oncology, UT-M D Anderson Cancer Center, Houston, TX, USA
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.477919.5 schema:alternateName Center for Cancer and Blood Disorders
305 schema:name Center for Cancer and Blood Disorders, Dallas, TX, USA
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...